Shire in preliminary talks with Barr on Adderall settlement

Shire Pharmaceuticals has confirmed that it is in preliminary talks with a rival generic drug company to settle litigation over its hyperactivity drug Adderall. News of the talks instantly sent Shire shares higher. Shire has been involved in litigation with Barr Pharmaceuticals, which is looking to release a generic version of Adderall. Shire has said it will defend its patent on Adderall until it expires in 2018, but now says it won't rule out a deal that opens the way to a cheaper medication prior to that.

- read this story from the BBC for more

Suggested Articles

The public financing will enable Monopar to start a phase 3 trial of a prophylactic treatment for a side effect of chemoradiotherapy. 

The dispute centers on whether Asa Abeliovich used Alector’s confidential information in connection with his work for Prevail Therapeutics.

GSK poaches Merck KGaA's Martinez-Davis to helm pharma stateside; Bulto named Novartis U.S. pharma head; Allergan's Saunders set for huge parachute.